PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Clinical Trial Supply West Coast Conference 2019: PCI’s Rich Nelson to Discuss Best Practices in the Global Movement of Scheduled Drug Product

Focusing on ‘Scheduled Drug – Processes and Complications in Global Logistics’, PCI’s Rich Nelson, Senior Manager, Global Logistics for Clinical Services, will present on Tuesday, May 14 at 9am PDT. Rich will share PCI’s significant experience, providing an overview of the differences and potential difficulties involved with the global movement of scheduled drugs. He will also discuss the impact of those processes on timelines and logistics plans for clinical trials.

In his role with PCI, Rich works with clients to provide seamless global distribution for their investigational drug products, ensuring cost-effective and time-efficient delivery throughout the clinical trials process.

“The process of handling scheduled drugs is highly complex, due to the inherent risks involved with the product, and the need for absolute compliance in its development, manufacturing and distribution. PCI has a long-standing track record of supporting clients across the world in this challenging area, and I am delighted to have the opportunity to share some of our insight and experience at the CTS West Coast event,” said Rich. 

PCI recently announced expansion of its industry leading global controlled substance infrastructure, coinciding with new legislation from the US government in addressing concerns about the nations’ opioid crisis.  PCI offers expertise in packaging and logistics for controlled substances, approved for Schedule I – V DEA designations.  PCI’s domestic operations are located in Philadelphia, PA, Rockford, IL, and San Diego, CA, complemented by operations in the UK, Ireland and Australia.

PCI is a trusted partner for the global healthcare industry and has been providing development solutions that increase client’s products’ speed to market and opportunities for commercial success. PCI has proven experience that comes with more than 50 successful product launches a year and over five decades in the healthcare business. Many clients view PCI as an extension of their business and a collaborative partner, with the shared goal of improving patients’ lives.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026